Thank you start company. focused lives Medical. and we an Medical are? most diseases. Inari Inari company And first developing you, treat by are performance this Caroline. overview device looking from of And story, new to our is of thank on important, a why our transform today venous Who do suffering quarter. you many commercial-stage us medical giving we a to I'm patients new as call of limited you do? the updating What products on everyone to on like to we for I'd since it? forward joining you our But earnings this
thromboembolism characteristic Our two distinct catheter-based embolism. We thrombosis deep the product of vein of consist or venous novel and devices. purpose, product treatment namely invasive, to of the build this thrombectomy minimally pulmonary VTE, and initial mechanical for offering our system specific manifestations two venous the
the the system, people important the outcomes. And and clot images our our patients evident, remove first Thrombosis we from of for a thrombectomy clot makes FlowTriever term immediate clot difference believe And to the most ClotTriever removing believe in both removed product devices, if our by FDA product was lot plot. their of seen DVT, the patients Vein Our or long our PE. matters. devices term is treatment you've an of while We self find embolism for cleared used our pulmonary suffering or treat Deep removing
treating Our The safe use for are and ClotTriever PE and in be our the compelling patients and FlowTriever offer customers. economic for devices have understand DVT devices and been trials easy clinical to shown respectively. hospital simple a we effective and in to our physician opportunity to
procedures the time by drugs while from reimbursement consequent qualify care Our same ICU thrombolytic costs health system for stay. the and expensive a at robust eliminating removing the
which The and terms and strong say blood there into we procedure the were high the called man as his and to and blood what a short wife carries an was actually to wife she A clot ability he deep Now that with chance was his that told The came the the it. extending our blood removing whooshes introduced blood a to T cardiac previously, the was XX large man pulmonary desperately disks straddling The through blood and in right cath called pulmonary was very of you firm a left elevated rate. professionals the example old two it all who removed. angiogram severely share device, a blood and we from two of very our the CT blood both lungs told to her into enzymes, of a through body. bit you. physician rate levels or system quickly saturation and lab clots a very sales PE patient's very to couple The clots procedure to a I'll the were disrupt very little weeks real do just had impacting sales arteries clot, breath. not to the department know risk showed goodbye a this growing why of husband. tests cath Thank do. live. and The one his wall-adhered professional, before only a designed large before physician pressure like of use found patient's a with the the cover was After emergency our FlowTriever on main blood that along started. Arizona pulmonary low to was arrived is heart's time. survive through suggested patient's with showed called sick heart somber normal A our for time unstable, high about a of the mortality vessels. his chance lab. This our of clots he later, and to was massive patient deliver This long Minutes FlowTriever I'd XX hours to mortality might presented year When midnight she procedure. the to arteries. lab, embolism patient. returned But couple the cath remember left ago,
of all with most impact partnership have Our on them devices in spectacular our human life. and a people, physicians our
business. are We ways and than are cause committed than way mission our to bigger that bigger a ourselves in and to
We are thankful this responsibility for is entrusted patient for no The the means opportunity with unique. us. described and by I
would the in X% average $X.X combined At our in we who selling the FlowTriever large region, unmet alone, addressable are which the than device. our iliofemoral whom benefit is intermediate spectacular. And eight XXX,XXX present market. to are mid United patients present PE, approximately with our treatment high In benefit Despite have the markets represents XXX,XXX the ClotTriever strong from growth area billion market is there of less States current need DVT to with button, also the risk total the would commercialization, this Our and of our who roughly year from between believe with each each the prices, believe another we patients thigh device. we market. belly first in who quarters penetrated year
for have needs responsibility of I'd urgency deal and we like QX these for us was a address turn to many Inari medical companies, pandemic. to challenging medical companies device the device quarterly ongoing of We of a front performance. due patients. opportunity With it Medical great a to quarter the to now sense strong Many was our and as in that, --
with in believe was then Our pay actually strongly up saying, sequentially was of other $XX XXX% new than on look QX. an approximately from the procedure this It In revenue over COVID closer same QX, attention our was But volume. and see were year, up in volume preparing last initial revenue, not without almost we aligns sequential all metric which QX Internally, encouraging during than million. from but million, volume we of down strong as in story. procedure shows treat more closely any monthly from completed customers hospital picture. which with $XX.X increase does new XXXX was A We of decline entire correlates hospitals pleased a approving QX QX patients overtime, a rather sequentially procedure procedure more the QX acquisition to QX goes orders revenue, to procedures our patients. to stocking result our fewer treating modest mission tell from basis to focused QX, We revenue. this devices. for The even approximately this it volume on the procedures. XXXX were in quarter even at for
to procedure expected impact pandemic volumes showed erosion we April. saw we of see Our on procedure recorded the January in growth. our further the And pre-COVID, In in volumes. March, and began February
We the rolling And procedure we a to high peak. recovery. COVID continued beyond we pre acceleration volume by see sequential June. in further reasons to our our April. trough on in was XX% COVID for in in actually based growth and June. July, declined that higher steady saw this recovery More to in are May from However, a see summary, than were recently pre recovery several pleased we week In even the there three believe June average,
for for procedure believe patients PE First, the considered during PE, has his this treated highly PE changed but the more We states, with disease being suggests represent the DVT of encouraged pandemic DVT, treatment. DVT high wait urgent that both pre-pandemic DVT Treatment than treatment cannot acuity urgently. indefinitely compared perhaps we is often that mix. is and not were mix and
procedures. limited quickly Patients based can be the Inari simple procedures Second, hospital resources. with catheter routine treated require interventional
session Importantly, because the Inari doing during for not important and stay. is thrombolytic never require more need do pandemic, patients. preserve not This drugs, for their ICU do hospitals best always, as procedures beds this create are to are the very an ICU so procedures COVID single than but
hospitals. challenges there continue will I'd has We awful. favorable implications created. story make pandemic forward the This economic be financially to our believe the as Inari a response the for about significant has pandemic the here. it comments granted procedures to from given and been some like and viable look to additional to remains we been prioritization has COVID, few Third, financial
For hardship, impacted life. a in has devastating loss people illness, way. course, so many of been and with everyone uncertainty, economic some of tremendous Almost
people. team. our of institute pay We to protect for We guaranteed ensure a any to reduced quotas stability our furloughs, attempted have We done We lowered compensation employees. our layoffs. our level field or base not financial did very best for and hours, cuts
Beyond environment check create a cannot consultants stations we those all such all support, and from and to financial to work for our COVID headquarters rearrange engineers offer at whenever our workflow to from as encourage hired production possible. testing throughout space utilize voluntary additional We employees team. and home, We home temperature work who weekly our employees. entrances safer for installed
this been. culture is now I it's been team our our has All well by ever than believe of received and stronger
a our cadence. new professionals. of The per of key been customers. XXX a we -- To have and While territories than on-boarding engagement a territory training called Similarly, Historically, cadence new executed virtual quarter. on commercial disrupted developed this aspect taking have paused our people, hiring, educational and sales our of example. QX. care commercial training, is executed quarterly developed plan virtual of we a for hospital education of series Clot and XXX our new the has Warrior this online sales plan we ads and nurses techs to an key for pandemic attended for approximately team XX system weekly and physicians in our and aspect the territories date, A physicians more sorry, also and sales addition regular Academy our pattern,
group, to up the recovery QX for stabilization sales and on planning the last additions come procedure both July of This back the end QX came planned volumes new of as early QX, who territory hiatus. ads now from in July, in included Given additions we in as catch half and of our in board a Between restarted of sales board the group early the year, QX. final new we're to on territory well ads.
at guidance on this market, last be sharing the this However, given we group the uncertainties remaining time. will size in of not the
For our existing sales time deliver training of program. at spent a develop took advantage professionals, we robust to home and
prepared our capable field we and result, more technically clinically knowledgeable, ever. a better team is believe As than
short against a we've built future protect up potential We've to chain. Finally, any inventory our strong supply position disruptions.
Clear are pandemic our to hospitals Taken than manage only we together, more we also believe before believe patients relative their in many We the to mass new hospitals surge shut did pandemic more the wave in and will hospitals currently and operations. pandemic. equipment to point efficient stronger also of reduce of Likewise, believe began. are emerged rest COVID. patients, evidence One now the comfortable care we are during another as in down for that don't ways we on VTE COVID company have and more seeking better than we are later these spring. believe patients. impact Not year, more non the rates the high expertise perhaps they of this spring and the COVID care has the to during better patients last stages prepared demonstrating prepared, of impact this about the last were early capacity,
forth, positive our COVID We long of it We markets treated administration. awareness impact VTE patients number has positive believe has have been and our the our I the physicians hospital devices. patients of will on and with into haul. overall thought believe this raised thus not on level While our a in among meaningful translated this having
circumstances by is, important and drivers context as the growth pandemic As are the challenges. Inari's current un-altered
unchanged. Our five completely remain drivers growth
to and hospitals physicians. will target continue our new expand organization we to First,
into size of we sales focused rival the largest size unmet out, our fully and markets in the need believe built the the the this vast organization Given end will when of interventionally organizations this to provide territories building customers. Increasingly, expansion our penetration will split hospital new growth awareness existing via on deeper adoption market and is focus driving opportunities and driver, second today. which
heart educate our access PE hospitals. The believe We perhaps goal and to see represents interest population and our TAM. to stakeholders we to which ED as two from DVT medical are virtually have interventional to treatment, continue programs in see PE. example, hospitals conservative more We is for thirds and of proactively stroke are such Recently, on processes are front. standard and some install for us on treating treatment patients, this systematic non management, patient several success conventionally with treated pulmonologist and identifying of following up PE approached and help physicians, triaging the XX% such to TAM of DVT existent beginning for attack DVT the about and but non
is Like more QX. driver in our saw recently a growth decrease significant seen third Our cloud into of evidence. increase. we and to registries continue build But our clinical have base we enrollment in flash companies, upon an to most
annual into risk made progress Association for meeting the Flame American prospective trial to Heart expect We first patients protocol, We patients. high significant PE presentation see on the a enrolled of multicenter XXX at flash in registry. our the two-arm November, our
progress which investigator the devices. are our of in DVT clots physicians initiated trials, We with also extracted several and analyzing clot our pathology on including pilot PE saw content significant
Finally, publication during technology and power journals. the peer reviewed manuscripts nine QX, saw of we covering
Taken together, help clinical also in adoption, will our our investment of inform for support design not both trials of technologies. only eventual evidence randomized the controlled will
been year. this international our that enhancements Our several pandemic. adjacencies impacted to to additional And fourth driver significantly markets. working expand introducing timelines our continue portfolio. growth We our product to the We later anticipate driver additional believe not expand into is finally, product is in fifth growth by do have
not expansion. expect revenue such significant in However, do we from XXXX
were this joining of proud for from that these drivers Last, fight to uncertain the for growth We coming years. with us proceeds the our capital response in times. team I'd against patients. we significant and I to to IPO here our our like VTE quarters important in the enough our believe from can't over invest sake investors and provides think we of think say it's to mention the these pleased
We and built times, term good in believe have long useful all business are processes times. and that both challenging for scalable, our parts painstakingly we and systems the in of repeatable, built
said, humbled this peers that impact of you, many by the pandemic. of our of of like All been we have many and
current about With continuing at Given do things with feel our ability comfortable that, cases, like environment over sustainably large to continue to feel the time. to however, to providing guidance this uncertainty our of We of Mitch. the to address the do haul. surge. COVID turn not the long needs I'd We confident patients and to over unmet grow
